2025-10-05 - Analysis Report
Okay, here's an analysis of Merck & Co. (MRK) based on the information you provided, formatted as requested:

## Merck & Co. (MRK) Stock Analysis

**0. Overview**

This report analyzes Merck & Co. (MRK), comparing its performance against the S&P 500 (VOO), examining technical indicators, recent news, analyst opinions, and financial data to provide a comprehensive investment perspective.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** MRK
*   **Company Description:** Merck & Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets a wide range of healthcare products.
*   **MRK Cumulative Return:** 5.45%
*   **VOO Cumulative Return:** 98.51%
*   **Absolute Deviation:**
    *   Max: 23.9
    *   Min: -103.9
    *   Current: -92.6
    *   Relative Deviation: 8.8

**Analysis:** MRK has significantly underperformed the S&P 500. The current deviation of -92.6 suggests substantial underperformance. A relative deviation of 8.8 indicates MRK's current underperformance is near the lower end of its historical range relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
|------------|--------|--------|---------|--------|--------|
| 2015-2017  | 1.0%   | 68.5%  | -28.0%  | 0.0    | 134.1  |
| 2016-2018  | 36.0%  | 69.8%  | 21.0%   | -0.0   | 182.1  |
| 2017-2019  | 40.0%  | 69.8%  | 18.0%   | 0.3    | 216.8  |
| 2018-2020  | 16.0%  | 79.6%  | -8.0%   | 0.3    | 195.0  |
| 2019-2021  | 2.0%   | 79.6%  | -44.0%  | 0.7    | 191.4  |
| 2020-2022  | 15.0%  | 79.6%  | 16.0%   | 0.7    | 277.1  |
| 2021-2023  | 33.0%  | 79.6%  | 31.0%   | 0.3    | 272.3  |
| 2022-2024  | -4.0%  | 79.6%  | -25.0%  | 0.2    | 248.5  |
| 2023-2025  | -44.0% | 71.5% | -107.0% | 1.5    | 222.8  |

**Analysis:**

*   **CAGR:** Varies significantly across periods. The recent period (2023-2025) shows a substantial decline.
*   **MDD:** High Maximum Drawdown values consistently, indicating significant volatility and risk.
*   **Alpha:** Mixed performance. Recent periods show strongly negative alpha, suggesting significant underperformance relative to its risk-adjusted benchmark.
*   **Beta:** Generally low (close to zero or below 1), implying MRK is less sensitive to market movements, except for the most recent period of 2023-2025, which shows a high beta of 1.5

**2. Recent Price Action**

*   **Current Price:** 89.19
*   **Previous Close:** 89.51
*   **Change:** -0.36
*   **5-day Moving Average:** 86.591
*   **20-day Moving Average:** 82.7977
*   **60-day Moving Average:** 82.7615

**Analysis:** The current price is slightly down from the previous close.  The price is above all three moving averages, suggesting a short-term upward trend. The 5-day moving average is above the 20-day and 60-day moving averages, further reinforcing the upward momentum.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 72.81 (Overbought)
*   **PPO:** 1.29
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (35 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Recent (20-day) Relative Deviation Change:** 8.8 (+) (Short-term Increase)
*   **Expected Return (%):** -64.5 (Long-term Underperformance vs. S&P 500)

**Analysis:**

*   **MRI:** Indicates a high investment recommendation, suggesting the stock is considered relatively safe despite other indicators.
*   **RSI:** Indicates that the stock is currently overbought, potentially signaling a pullback or consolidation.
*   **PPO:** Positive, confirming the recent upward trend.
*   **Hybrid Signal:** Recommends buying, allocating all available cash, suggesting a bullish outlook.
*   **Relative Deviation Change:** The positive change indicates short-term upward momentum.
*   **Expected Return:**  The expected return is significantly negative, suggesting considerable underperformance relative to the S&P 500 over the next two years or more.
*   **Last-market Change**: The recent price change of -0.36 is not significant enough to indicate a major volatility event.

**4. Recent News & Significant Events**

*   **[2025-10-04]** Jim Cramer on Danaher: “It Has Been a Huge Disappointment” (Indirectly relevant as it discusses sentiment on other healthcare stocks).
*   **[2025-10-03]** US Equity Indexes Rise This Week as AI-Trade Lifts Tech, Healthcare Gains Following Pfizer Deal (Positive for the sector generally).
*   **[2025-10-03]** 5 Large Cap Drug Stocks: Values or Traps? (Relevant, needs further investigation to see where MRK falls).
*   **[2025-10-03]** MRK Stock Up Nearly 14% So Far This Week: What's Driving It? (Very Positive - indicates recent positive catalyst).
*   **[2025-10-03]** What Does Wall Street Think About Merck & Co. (MRK)? (Important for understanding analyst sentiment).
*   **[2025-10-02]** Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? (Relevant if MRK is one of those stocks, indicating potential income appeal).

**Analysis:** The news is mixed. A general rise in healthcare due to the Pfizer deal and positive commentary on MRK's recent performance are bullish. However, the article about large-cap drug stocks being "values or traps" suggests caution. The article about Wall Street's opinion on MRK is important for understanding overall sentiment.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 2.00 (~Buy)
*   **Number of Opinions:** 25
*   **Target Price:**
    *   Average: 101.60
    *   High: 141.00
    *   Low: 82.00
*   **Recent Rating Changes:** No recent changes are indicated in the data provided.

**Analysis:** The analyst consensus is positive, with a "Buy" rating and a mean rating around 2.0. The average target price suggests potential upside. The high target price indicates some analysts are very optimistic.  The lack of recent rating changes suggests a stable outlook from analysts.

**5. Recent Earnings Analysis**

| 날짜         | EPS    | 매출         |
|--------------|--------|--------------|
| 2025-08-05   | 1.76   | 15.81 B$     |
| 2025-05-02   | 2.01   | 15.53 B$     |
| 2024-11-06   | 1.25   | 16.66 B$     |
| 2024-08-05   | 2.15   | 16.11 B$     |
| 2025-08-05   | 2.15   | 16.11 B$     |

**Analysis:** Earnings per share (EPS) and revenue have fluctuated. The most recent EPS (1.76) is lower than some prior quarters. Revenue also shows some variability. Further investigation is needed to understand the reasons behind these fluctuations and identify any trends.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | $15.81B    | 77.50%        |
| 2025-03-31   | $15.53B    | 77.98%        |
| 2024-12-31   | $15.62B    | 75.50%        |
| 2024-09-30   | $16.66B    | 75.51%        |
| 2024-06-30   | $16.11B    | 76.76%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE      |
|--------------|------------|----------|
| 2025-06-30   | $48.99B    | 9.04%    |
| 2025-03-31   | $48.34B    | 10.51%   |
| 2024-12-31   | $46.31B    | 8.08%    |
| 2024-09-30   | $44.50B    | 7.09%    |
| 2024-06-30   | $43.58B    | 12.52%   |

**Analysis:**

*   **Revenue:** Relatively stable over the past five quarters, with some fluctuation.
*   **Profit Margin:** Consistently high, indicating strong profitability.
*   **Equity:** Gradually increasing, suggesting positive growth in the company's net worth.
*   **ROE:**  Fluctuates, indicating varying levels of profitability relative to equity. A deeper dive is required to determine the source of these fluctuations.

**7. Overall Analysis & Recommendation**

Merck & Co. (MRK) presents a mixed investment picture.

**Strengths:**

*   **Strong Analyst Consensus:** Positive "Buy" rating and target prices suggest upside potential.
*   **High Profit Margins:** Consistently high profitability.
*   **MRI:** A high MRI score of 0.9 suggests a relatively safe investment.

**Weaknesses:**

*   **Significant Underperformance:** MRK has significantly underperformed the S&P 500, with a large negative deviation.
*   **Negative Expected Return:** Long-term expected underperformance relative to the S&P 500 is a major concern.
*   **RSI:** The stock is currently overbought, potentially signaling a pullback or consolidation.
*   **Mixed News:** While some recent news is positive, others warrant caution.
*   **Fluctuating EPS and Revenue:** Recent financial performance shows inconsistencies.

**Recommendation:**

Based on the information provided, a cautious approach is warranted.

*   **Existing Holders:** Consider re-evaluating your position, especially given the significant underperformance against the S&P 500 and the negative expected return.
*   **Potential Investors:** Further research is needed to understand the drivers behind the underperformance and the long-term growth prospects of the company. The analyst consensus is positive, but the negative expected return should be carefully considered. The recent news about the stock being up nearly 14% is a positive sign, but it's crucial to understand the catalyst behind this surge and whether it's sustainable.
*   **Hybrid Signal Recommendation:** The hybrid signal recommends buying. However, this should be viewed in the context of other indicators, particularly the negative expected return and the overbought RSI.

**Disclaimer:** This analysis is based solely on the information provided and does not constitute financial advice.  Consult with a qualified financial advisor before making any investment decisions.
